CT
MN
VT
NV
WA
1. Deprioritization/ Decriminalization
2. Non-Commercial Peer Sharing
3. Commercial Sales
4. Religious Use Exemptions
5. Supervised Adult Use
6. Medical/ Therapeutic Use
7. FDA-Approved Use
8. State Monopoly Sales
N/A
Endorsed
N/A
Supported
N/A
Opposed
Mixed
N/A
N/A
N/A
Opposed
Mixed
N/A
N/A
Supported
N/A
Supported
N/A
N/A
Endorsed
Opposed
Endorsed
Opposed
Endorsed
Endorsed
Endorsed
Endorsed
Mixed
Endorsed
Endorsed
Endorsed
Opposed
N/A
Opposed
Opposed
N/A
N/A
N/A
N/A
N/A
1.
Deprioritization/Decriminalization
Removal of criminal penalties or enforcement for personal use/possession.
CTN/A
MNEndorsed
VTN/A
NVSupported
WAN/A
2.
Non-Commercial Peer Sharing
Adults may grow and share psychedelics without sale or profit.
CTOpposed
MNMixed
VTN/A
NVN/A
WAN/A
3.
Commercial Sales
Licensed private businesses, cultivate, sell, and profit in a regulated market.
CTOpposed
MNMixed
VTN/A
NVN/A
WASupported
4.
Religious Use Exemptions
Use permitted within federally or judicially recognized religious contexts.
CTN/A
MNSupported
VTN/A
NVN/A
WAEndorsed
5.
Supervised Adult Use
Adults access psychedelics via licensed facilitators in non-medical settings.
CTOpposed
MNEndorsed
VTOpposed
NVEndorsed
WAEndorsed
6.
Medical/Therapeutic Use
Access via clinicians for patients with qualifying diagnoses; not FDA-approved.
CTEndorsed
MNEndorsed
VTMixed
NVEndorsed
WAEndorsed
7.
FDA-Approved Use
State controls supply, distribution, and pricing; private retail excluded.
CTEndorsed
MNOpposed
VTN/A
NVOpposed
WAOpposed
8.
State Monopoly Sales
Legalizes psilocybin sales only through state-run stores or agencies, prohibiting private commercial sales.
CTN/A
MNN/A
VTN/A
NVN/A
WAN/A